厄多斯坦市場機會、成長動力、產業趨勢分析和 2025 年至 2034 年預測

2024 年全球厄多司坦市場價值為5,420 萬美元，預計2025 年至2034 年複合年成長率為8.1%。的有效性而越來越受歡迎像慢性支氣管炎。隨著呼吸系統疾病變得越來越普遍，特別是那些與黏液積聚有關的疾病，對厄多司坦的需求不斷增加，因為它能夠減輕發作期間的症狀。

人們日益轉向疾病預防，加上政府對醫療保健的資助增加，導致研究機構厄多司坦使用量的增加。全球患有糖尿病、肥胖症和心血管疾病等慢性健康問題的成年人口不斷增加，進一步推動了對有效治療的需求，從而推動了藥物研究和厄多司坦市場。

厄多司坦因其在處理粘液相關問題方面的有效性而成為粘液溶解劑的首選。它相對於傳統治療的潛在優勢引起了製藥公司的極大關注，這些公司專注於改進藥物配方和改進輸送機制。新興經濟體醫療保健基礎設施的發展也透過增加厄多司坦的取得而促進了市場的成長。

受吸煙和空氣品質差等因素影響，慢性阻塞性肺病（COPD）病例不斷增加，推動了對厄多司坦等有效黏液溶解藥物的需求。隨著全球環境污染和呼吸系統疾病的惡化，對能夠治療這些疾病的藥物的需求不斷成長。製藥市場的持續擴張進一步支持了這一趨勢，該市場正在推動創新並提高治療的可用性。

到2034 年，COPD 細分市場預計將實現5,020 萬美元的收入，複合年成長率為8%。需求。

2024 年，製藥領域佔據 42.9% 的市場佔有率，價值 2,140 萬美元，預計 2025 年至 2034 年複合年成長率為 7.9%。 技術進步、老年人口不斷成長以及研發投資的增加預計將推動該細分市場市場的成長。

新興經濟體的經濟顯著成長和醫療保健支出增加，這對厄多司坦市場產生了積極影響。隨著呼吸系統治療需求的增加，特別是在呼吸系統疾病高發生率地區，製藥業預計將持續成長。

在美國，厄多司坦市場預計將達到2,180萬美元，2025年至2034年複合年成長率為6.3%。發病率，從而進一步刺激市場。傳統捲菸替代品的日益普及也導致了慢性阻塞性肺病病例的增加，為厄多司坦市場創造了新的機會。

目錄

第 1 章：方法與範圍

第 2 章：執行摘要

第 3 章：產業洞察

• 產業生態系統分析
  • 影響價值鏈的因素
  • 利潤率分析
  • 干擾
  • 未來展望
  • 製造商
  • 經銷商
• 供應商格局
• 利潤率分析
• 重要新聞和舉措
• 監管環境
• 衝擊力
• 產業影響力
  • 成長動力
    • 吸菸和接觸菸草煙霧的趨勢日益明顯，導致慢性阻塞性肺病（COPD）發生率增加
    • 暴露於污染的空氣品質會導致支氣管炎等嚴重疾病的發生
    • 醫藥市場拓展
  • 市場挑戰
    • 藥物對某些健康狀況的限制
• 法規和市場影響
• 波特的分析
• PESTEL分析

第 4 章：競爭格局

• 介紹
• 公司市佔率分析
• 競爭定位矩陣
• 戰略展望矩陣

第 5 章：市場規模與預測：按應用分類，2021-2034 年

• 主要趨勢
• 支氣管炎
• 慢性阻塞性肺病
• 鼻咽炎
• 其他

第 6 章：市場規模與預測：依最終用途，2021-2034 年

• 主要趨勢
• 製藥
• 首席行銷長
• 科學研究機構

第 7 章：市場規模與預測：按地區分類，2021-2034 年

• 主要趨勢
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 英國
  • 德國
  • 法國
  • 義大利
  • 西班牙
  • 俄羅斯
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲
• 拉丁美洲
  • 巴西
  • 墨西哥
• MEA
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國

第 8 章：公司簡介

• Apotex Inc.
• Cipla Ltd.
• Dr. Reddy's Laboratories
• Hanmi Pharmaceutical
• Hikma Pharmaceuticals
• Mylan NV
• Recipharm AB
• Sandoz
• Shandong Luoxin Pharmaceutical
• Zhejiang Kangle Pharmaceutical Co., Ltd

The Global Erdosteine Market, valued at USD 54.2 million in 2024, is projected to grow at a CAGR of 8.1% from 2025 to 2034. Erdosteine, known for its free radical scavenging and mucolytic properties, is gaining popularity due to its effectiveness in treating conditions like chronic bronchitis. As respiratory diseases become more prevalent, especially those related to mucus accumulation, the demand for erdosteine is increasing, driven by its ability to reduce symptoms during flare-ups.

The growing shift toward disease prevention, combined with increased government funding for healthcare, is contributing to the rise in erdosteine usage in research institutions. The expanding global population of adults with chronic health issues, such as diabetes, obesity, and cardiovascular diseases, is further fueling the need for effective treatments, thereby boosting pharmaceutical research and the erdosteine market.

Erdosteine is becoming a preferred choice as a mucolytic agent due to its effectiveness in managing mucus-related issues. Its potential benefits over conventional treatments are drawing significant attention from pharmaceutical companies, which are focusing on advancing drug formulations and improving delivery mechanisms. The development of healthcare infrastructure in emerging economies is also contributing to the market's growth by increasing access to erdosteine.

The rising cases of chronic obstructive pulmonary disease (COPD), influenced by factors such as smoking and poor air quality, are pushing the demand for effective mucolytic treatments like erdosteine. As environmental pollution and respiratory conditions worsen globally, the need for medications capable of managing these ailments is growing. This trend is further supported by the ongoing expansion of the pharmaceutical market, which is driving innovations and enhancing the availability of treatments.

The COPD segment is expected to capture USD 50.2 million and show an 8% CAGR by 2034. The aging population and the growing incidence of smoking are key factors contributing to the rise in COPD cases, thereby boosting demand for erdosteine.

In 2024, the pharmaceutical segment held 42.9% of the market, worth USD 21.4 million, and is expected to grow at a 7.9% CAGR from 2025 to 2034. Advances in technology, a growing geriatric population, and increased investment in R&D are expected to drive the growth of this segment.

Emerging economies are seeing significant economic growth and increased healthcare expenditure, which is positively influencing the erdosteine market. As demand for respiratory treatments rises, particularly in regions with a high prevalence of respiratory diseases, the pharmaceutical sector is expected to experience continued growth.

In the U.S., the erdosteine market is anticipated to reach USD 21.8 million, growing at a CAGR of 6.3% from 2025 to 2034. Increased smoking rates, particularly among younger populations, are expected to raise the incidence of COPD, further stimulating the market. The growing popularity of alternatives to traditional cigarettes is also contributing to the rise in COPD cases, creating new opportunities for the erdosteine market.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definition
• 1.2 Base estimates & calculations
• 1.3 Forecast calculation
• 1.4 Data sources
  • 1.4.1 Primary
  • 1.4.2 Secondary
    • 1.4.2.1 Paid sources
    • 1.4.2.2 Public sources

Chapter 2 Executive Summary

• 2.1 Industry synopsis, 2021-2034

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
  • 3.1.1 Factor affecting the value chain
  • 3.1.2 Profit margin analysis
  • 3.1.3 Disruptions
  • 3.1.4 Future outlook
  • 3.1.5 Manufacturers
  • 3.1.6 Distributors
• 3.2 Supplier landscape
• 3.3 Profit margin analysis
• 3.4 Key news & initiatives
• 3.5 Regulatory landscape
• 3.6 Impact forces
• 3.7 Industry impact forces
  • 3.7.1 Growth drivers
    • 3.7.1.1 Growing trends towards cigarette smoking and exposure to tobacco smoke leading to increase in COPD
    • 3.7.1.2 Exposure to polluted air quality leading to development of serious medical conditions like bronchitis
    • 3.7.1.3 Pharmaceutical market expansion
  • 3.7.2 Market challenges
    • 3.7.2.1 Limitation of the drug with certain medical condition
• 3.8 Regulations & market impact
• 3.9 Porter's analysis
• 3.10 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Competitive positioning matrix
• 4.4 Strategic outlook matrix

Chapter 5 Market Size and Forecast, By Application, 2021-2034 (USD Million) (Tons)

• 5.1 Key trends
• 5.2 Bronchitis
• 5.3 COPD
• 5.4 Nasopharyngitis
• 5.5 Others

Chapter 6 Market Size and Forecast, By End Use, 2021-2034 (USD Million) (Tons)

• 6.1 Key trends
• 6.2 Pharmaceutical
• 6.3 CMOs
• 6.4 Research institutes

Chapter 7 Market Size and Forecast, By Region, 2021-2034 (USD Million) (Tons)

• 7.1 Key trends
• 7.2 North America
  • 7.2.1 U.S.
  • 7.2.2 Canada
• 7.3 Europe
  • 7.3.1 UK
  • 7.3.2 Germany
  • 7.3.3 France
  • 7.3.4 Italy
  • 7.3.5 Spain
  • 7.3.6 Russia
• 7.4 Asia Pacific
  • 7.4.1 China
  • 7.4.2 India
  • 7.4.3 Japan
  • 7.4.4 South Korea
  • 7.4.5 Australia
• 7.5 Latin America
  • 7.5.1 Brazil
  • 7.5.2 Mexico
• 7.6 MEA
  • 7.6.1 South Africa
  • 7.6.2 Saudi Arabia
  • 7.6.3 UAE

Chapter 8 Company Profiles

• 8.1 Apotex Inc.
• 8.2 Cipla Ltd.
• 8.3 Dr. Reddy's Laboratories
• 8.4 Hanmi Pharmaceutical
• 8.5 Hikma Pharmaceuticals
• 8.6 Mylan N.V.
• 8.7 Recipharm AB
• 8.8 Sandoz
• 8.9 Shandong Luoxin Pharmaceutical
• 8.10 Zhejiang Kangle Pharmaceutical Co., Ltd